Bridging Group Mechanisms of Leukemogenesis

Cancer patients die from resistance to therapy and metastasis. These processes are based on genetic and epigenetic aberrations and require the support of the tumor microenvironment that supplies pro-survival and protective stimuli. Understanding the molecular mechanism of these processes will allow one to target aberrant (epi)genetic pathways, interrupt the support of the microenvironment and address resistance to therapy. The Cooperation Unit between the DKFZ and the University Hospital of Ulm is ideally suited to translate molecular findings on chronic leukemia towards clinical application with respect to prognostication and therapy.

Overview of projects:

1. The microenvironment as a therapeutic target in chronic lymphocytic leukemia.
2. Ubiquitination and NOTCH1 signaling in leukemia.
3. Epigenetic aberrations explain leukemogenesis and help prognostication of patients.